|
1
|
Verheul HM, Hammers H, van Erp K, Wei Y,
Sanni T, Salumbides B, Qian DZ, Yancopoulos GD and Pili R: Vascular
endothelial growth factor trap blocks tumor growth, metastasis
formation, and vascular leakage in an orthotopic murine renal cell
cancer model. Clin Cancer Res. 13:4201–4208. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Paez-Ribes M, Allen E, Hudock J, Takeda T,
Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D and Casanovas O:
Antiangiogenic therapy elicits malignant progression of tumors to
increased local invasion and distant metastasis. Cancer Cell.
15:220–231. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zuniga RM, Torcuator R, Jain R, Anderson
J, Doyle T, Ellika S, Schultz L and Mikkelsen T: Efficacy, safety
and patterns of response and recurrence in patients with recurrent
highgrade gliomas treated with bevacizumab plus irinotecan. J
Neurooncol. 91:329–336. 2009. View Article : Google Scholar
|
|
4
|
Shojaei F, Wu X, Malik AK, Zhong C,
Baldwin ME, Schanz S, Fuh G, Gerber HP and Ferrara N: Tumor
refractoriness to anti-VEGF treatment is mediated by
CD11b+Gr1+ myeloid cells. Nat Biotechnol.
25:911–920. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Soeda S, Nakamura N, Ozeki T, Nishiyama H,
Hojo H, Yamada H, Abe M and Sato A: Tumor-associated macrophages
correlate with vascular space invasion and myometrial invasion in
endometrial carcinoma. Gynecol Oncol. 109:122–128. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kischel P, Waltregny D, Dumont B, Turtoi
A, Greffe Y, Kirsch S, De Pauw E and Castronovo V: Versican
overexpression in human breast cancer lesions: Known and new
isoforms for stromal tumor targeting. Int J Cancer. 126:640–650.
2010. View Article : Google Scholar
|
|
7
|
Wang W, Xu GL, Jia WD, Ma JL, Li JS, Ge
YS, Ren WH, Yu JH and Liu WB: Ligation of TLR2 by versican: A link
between inflammation and metastasis. Arch Med Res. 40:321–323.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim S, Takahashi H, Lin WW, Descargues P,
Grivennikov S, Kim Y, Luo JL and Karin M: Carcinoma-produced
factors activate myeloid cells through TLR2 to stimulate
metastasis. Nature. 457:102–106. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gao D, Joshi N, Choi H, Ryu S, Hahn M,
Catena R, Sadik H, Argani P, Wagner P, Vahdat LT, et al: Myeloid
progenitor cells in the premetastatic lung promote metastases by
inducing mesenchymal to epithelial transition. Cancer Res.
72:1384–1394. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ling Y, Yang Y, Lu N, You QD, Wang S, Gao
Y, Chen Y and Guo QL: Endostar, a novel recombinant human
endostatin, exerts antiangiogenic effect via blocking VEGF-induced
tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem
Biophys Res Commun. 361:79–84. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang HL, Ning T, Li M, Lu ZJ, Yan X, Peng
Q, Lei N, Zhang H and Luo F: Effect of endostatin on preventing
postoperative progression of distant metastasis in a murine lung
cancer model. Tumori. 97:787–793. 2011.
|
|
12
|
Ning T, Yan X, Lu ZJ, Wang GP, Zhang NG,
Yang JL, Jiang SS, Wu Y, Yang L, Guan YS, et al: Gene therapy with
the angiogenesis inhibitor endostatin in an orthotopic lung cancer
murine model. Hum Gene Ther. 20:103–111. 2009. View Article : Google Scholar
|
|
13
|
Ning T, Jiang M, Peng Q, Xi Y, Lu ZJ, Peng
YL, Wang HL, Lei N, Zhang H, Lin HJ, et al: Low-dose endostatin
normalizes the structure and function of tumor vasculature and
improves the delivery and anti-tumor efficacy of cytotoxic drugs in
a lung cancer xenograft murine model. Thorac Cancer. 3:229–238.
2012. View Article : Google Scholar
|
|
14
|
Huang G and Chen L: Discrepancies between
antiangiogenic and antitumor effects of recombinant human
endostatin. Cancer Biother Radiopharm. 24:589–596. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang H, Wang Z, Peng Q, Liu YY, Zhang W,
Wu L, Wang X and Luo F: Tumor refractoriness to endostatin
anti-angiogenesis is associated with the recruitment of CD11b+Gr1+
myeloid cells and inflammatory cytokines. Tumori. 99:723–733.
2013.
|
|
16
|
Li XQ, Shang BY, Wang DC, Zhang SH, Wu SY
and Zhen YS: Endostar, a modified recombinant human endostatin,
exhibits synergistic effects with dexamethasone on angiogenesis and
hepatoma growth. Cancer Lett. 301:212–220. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ben-Neriah Y and Karin M: Inflammation
meets cancer, with NF-κB as the matchmaker. Nat Immunol.
12:715–723. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hernández D, Miquel-Serra L, Docampo MJ,
Marco-Ramell A and Bassols A: Role of versican V0/V1 and CD44 in
the regulation of human melanoma cell behavior. Int J Mol Med.
27:269–275. 2011.
|
|
19
|
Zheng PS, Wen J, Ang LC, Sheng W,
Viloria-Petit A, Wang Y, Wu Y, Kerbel RS and Yang BB: Versican/PG-M
G3 domain promotes tumor growth and angiogenesis. FASEB J.
18:754–756. 2004.PubMed/NCBI
|
|
20
|
Ostrand-Rosenberg S and Sinha P:
Myeloid-derived suppressor cells: Linking inflammation and cancer.
J Immunol. 182:4499–4506. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gabrilovich DI and Nagaraj S:
Myeloid-derived suppressor cells as regulators of the immune
system. Nat Rev Immunol. 9:162–174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shojaei F, Wu X, Qu X, Kowanetz M, Yu L,
Tan M, Meng YG and Ferrara N: G-CSF-initiated myeloid cell
mobilization and angiogenesis mediate tumor refractoriness to
anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA.
106:6742–6747. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carbone C, Moccia T, Zhu C, Paradiso G,
Budillon A, Chiao PJ, Abbruzzese JL and Melisi D: Anti-VEGF
treatment-resistant pancreatic cancers secrete proinflammatory
factors that contribute to malignant progression by inducing an EMT
cell phenotype. Clin Cancer Res. 17:5822–5832. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gordon S and Taylor PR: Monocyte and
macrophage heterogeneity. Nat Rev Immunol. 5:953–964. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pollard JW: Trophic macrophages in
development and disease. Nat Rev Immunol. 9:259–270. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sica A and Bronte V: Altered macrophage
differentiation and immune dysfunction in tumor development. J Clin
Invest. 117:1155–1166. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Martinez FO, Helming L and Gordon S:
Alternative activation of macrophages: An immunologic functional
perspective. Annu Rev Immunol. 27:451–483. 2009. View Article : Google Scholar
|
|
28
|
Mantovani A, Bottazzi B, Colotta F,
Sozzani S and Ruco L: The origin and function of tumor-associated
macrophages. Immunol Today. 13:265–270. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mantovani A and Sica A: Macrophages,
innate immunity and cancer: Balance, tolerance, and diversity. Curr
Opin Immunol. 22:231–237. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qian BZ and Pollard JW: Macrophage
diversity enhances tumor progression and metastasis. Cell.
141:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sica A, Saccani A and Mantovani A:
Tumor-associated macrophages: A molecular perspective. Int
Immunopharmacol. 2:1045–1054. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim YJ, Jung EB, Lee MS, Seo SJ, Kim MH,
Lee MW and Lee CS: Rotundarpene inhibits toll-like receptor 2
activation-induced production of inflammatory mediators in
keratinocytes by suppressing the Akt and NF-κB pathways. Int
Immunopharmacol. 18:325–332. 2014. View Article : Google Scholar : PubMed/NCBI
|
